Aligos Therapeutics, Inc. Net Income Loss

• Aligos Therapeutics, Inc. showed an increase of +81.6% in Net Income Loss from 2024 to 2025.
• This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Aligos Therapeutics, Inc.'s Net Income Loss has grown by 53.7%.
• Historical annual values: Fiscal year 2025: -$24.19 million | Fiscal year 2024: -$131.21 million | Fiscal year 2023: -$87.68 million | Fiscal year 2022: -$96.05 million | Fiscal year 2021: -$128.33 million | Fiscal year 2020: -$108.54 million | Fiscal year 2019: -$52.26 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026